Vertex Pharmaceuticals stock (VRTX) has surged due to FDA approval of Journavx, positive impact on revenue.

From Nasdaq: 2025-02-02 22:17:52

Vertex Pharmaceuticals stock (NASDAQ: VRTX) surged after FDA approval of Journavx, a non-opioid pain medication with a potential $4 billion in annual sales. Investors reacted positively with a 9% after-market rally. Vertex’s revenue growth is driven by Trikafta/Kaftrio for cystic fibrosis, contributing 93% of sales. Operating margin declined due to increased R&D spending. The Trefis High-Quality Portfolio has outperformed the S&P 500.

VRTX stock has risen 106% from $220 to $450, with a P/S ratio increase to 11.0x and revenue growth to $10.6 billion. Trikafta/Kaftrio’s success has boosted sales, while Casgevy awaits peak sales of over $2 billion. Operating margin decreased due to higher R&D expenses.

Investors have rewarded VRTX stock with a higher valuation multiple as Trikafta demand increases. Despite volatility, the stock has shown mixed returns in recent years. The Trefis High-Quality Portfolio offers a more stable alternative with better performance than the S&P 500.

Looking ahead, VRTX stock may continue to rise as it trades at a higher P/S ratio due to strong Trikafta sales and Journavx approval. Comparisons with peers show Vertex Pharmaceuticals’ solid performance. The Trefis Reinforced Value Portfolio has significantly outperformed the S&P 500 since 2016.

In January 2025, VRTX stock returned 9% MTD and 8% YTD, with a total return of 495% since 2017. The S&P 500 returned 3% MTD, 27% YTD, and 171% since 2017. The Trefis Reinforced Value Portfolio had returns of 6% MTD, 23% YTD, and 801% since 2017, showcasing its market-beating performance.



Read more at Nasdaq: Should You Pick VRTX Stock At $450?